| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Departments of Anesthesia and Medicine and Division of Cardiology (M.R., M.E.P.-I., Y.M., A.D.A., S.M., J.F.-M., E.F., R.R., M.L.A., T.S.M., A.B., K.U., T.H., P.A., A.L., J.K.), Brigham and Womens Hospital, Harvard Medical School, Boston, Mass; and Institute of Molecular Cardiology (R.B.), University of Louisville, Ky.
Correspondence to Marcello Rota, PhD, Departments of Anesthesia and Medicine and Division of Cardiology, Brigham & Womens Hospital, Harvard Medical School, Boston, MA 02115. E-mail mrota{at}zeus.bwh.harvard.edu
Ischemic heart disease is characterized chronically by a healed infarct, foci of myocardial scarring, cavitary dilation, and impaired ventricular performance. These alterations can only be reversed by replacement of scarred tissue with functionally competent myocardium. We tested whether cardiac progenitor cells (CPCs) implanted in proximity of healed infarcts or resident CPCs stimulated locally by hepatocyte growth factor and insulin-like growth factor-1 invade the scarred myocardium and generate myocytes and coronary vessels improving the hemodynamics of the infarcted heart. Hepatocyte growth factor is a powerful chemoattractant of CPCs, and insulin-like growth factor-1 promotes their proliferation and survival. Injection of CPCs or growth factors led to the replacement of
42% of the scar with newly formed myocardium, attenuated ventricular dilation and prevented the chronic decline in function of the infarcted heart. Cardiac repair was mediated by the ability of CPCs to synthesize matrix metalloproteinases that degraded collagen proteins, forming tunnels within the fibrotic tissue during their migration across the scarred myocardium. New myocytes had a 2n karyotype and possessed 2 sex chromosomes, excluding cell fusion. Clinically, CPCs represent an ideal candidate cell for cardiac repair in patients with chronic heart failure. CPCs may be isolated from myocardial biopsies and, following their expansion in vitro, administered back to the same patients avoiding the adverse effects associated with the use of nonautologous cells. Alternatively, growth factors may be delivered locally to stimulate resident CPCs and promote myocardial regeneration. These forms of treatments could be repeated over time to reduce progressively tissue scarring and expand the working myocardium.
Key Words: cardiac repair cardiac stem cells chronic myocardial infarct
This article has been cited by other articles:
![]() |
K. M. Fischer, C. T. Cottage, W. Wu, S. Din, N. A. Gude, D. Avitabile, P. Quijada, B. L. Collins, J. Fransioli, and M. A. Sussman Enhancement of Myocardial Regeneration Through Genetic Engineering of Cardiac Progenitor Cells Expressing Pim-1 Kinase Circulation, November 24, 2009; 120(21): 2077 - 2087. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. D'Alessandro, J. Kajstura, T. Hosoda, A. Gatti, R. Bello, F. Mosna, S. Bardelli, H. Zheng, D. D'Amario, M. E. Padin-Iruegas, et al. Progenitor Cells From the Explanted Heart Generate Immunocompatible Myocardium Within the Transplanted Donor Heart Circ. Res., November 20, 2009; 105(11): 1128 - 1140. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ferreira-Martins, C. Rondon-Clavo, D. Tugal, J. A. Korn, R. Rizzi, M. E. Padin-Iruegas, S. Ottolenghi, A. De Angelis, K. Urbanek, N. Ide-Iwata, et al. Spontaneous Calcium Oscillations Regulate Human Cardiac Progenitor Cell Growth Circ. Res., October 9, 2009; 105(8): 764 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, M. N. Jameel, Q. Li, A. Mansoor, X. Qiang, C. Swingen, C. Panetta, and J. Zhang Stem Cells for Myocardial Repair With Use of a Transarterial Catheter Circulation, September 15, 2009; 120(11_suppl_1): S238 - S246. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Padin-Iruegas, Y. Misao, M. E. Davis, V. F.M. Segers, G. Esposito, T. Tokunou, K. Urbanek, T. Hosoda, M. Rota, P. Anversa, et al. Cardiac Progenitor Cells and Biotinylated Insulin-Like Growth Factor-1 Nanofibers Improve Endogenous and Exogenous Myocardial Regeneration After Infarction Circulation, September 8, 2009; 120(10): 876 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Quevedo, K. E. Hatzistergos, B. N. Oskouei, G. S. Feigenbaum, J. E. Rodriguez, D. Valdes, P. M. Pattany, J. P. Zambrano, Q. Hu, I. McNiece, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity PNAS, August 18, 2009; 106(33): 14022 - 14027. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Boudoulas and A. K. Hatzopoulos Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease Dis. Model. Mech., July 1, 2009; 2(7-8): 344 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Patane and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur. Heart J., May 2, 2009; 30(10): 1169 - 1170. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |